logo
Plus   Neg
Share
Email

Fossil Q1 Profit Grows - Quick Facts

Fossil Inc.'s (FOSL) first-quarter net income attributable to the company increased to $58.14 million or $0.93 per share from $55.82 million or $0.86 per share last year. On average, 15 analysts polled by Thomson Reuters expected earnings per share of $0.92 for the quarter. Analysts' estimates typically exclude one-time items.

The company said the recent quarter's results included a $0.03 per share rise related to net foreign currency exchange gains in comparison to the prior fiscal year first quarter and a $0.03 per share increase related to a 3.7% lower outstanding share count as a result of the company's ongoing buyback program.

Net sales increased 9.8% to $589.5 million from $537.0 million in the earlier year quarter, and up 11.1% in constant dollars. Thirteen analysts estimated revenues of $617.64 million for the quarter.

For the second quarter of fiscal 2012, the company sees reported net sales to increase about 16% with constant dollar net sales increasing 19%. Including Skagen activities, second quarter 2012 earnings per share are expected to be in a range of $0.77 - $0.79. Analysts expect earnings of $0.94 per share for the second quarter.

For fiscal 2012, the company currently projects reported net sales to increase around 16% with constant dollar net sales increasing nearly 18%. Net sales of Skagen, included in this estimate, are expected to benefit overall sales growth by 5%. Full-year earnings per share are now estimated to be in a range of $5.30 - $5.40, while 15 analysts project 2012 earnings of $5.56 per share.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
An administrative law judge has ruled that Minnesota regulators should approve Enbridge Inc.'s proposal to replace its aging Line 3 crude oil pipeline only if the company follows the existing route and not its preferred route. Enbridge has applied to replace its Line 3 pipeline from Alberta with new pipe along its existing route. In Minnesota, the planned route deviates from the existing route. CLICK HERE to see America's 10 Best-Selling Drugs Despite high drug costs, most of the top-selling drugs saw sales gains in 2017 compared to the prior year. A large number of the best-selling drugs are primarily for the treatment and management of cancer, diabetes, inflammatory disorders, and HIV... Most Americans have access to health care, though costs and services vary from state to state. However, higher costs do not necessarily translate into better results. The U.S. continues to be outperformed by other wealthy nations on several measures like life expectancy, disease burden and health...
Follow RTT